Information-Rich Drug Discovery Enabled by Next-Generation Multiplexing SPR
March 20, 2024
Overview
Detailed validation is key in successful drug development. Surface plasmon resonance (SPR) offers a label-free, direct-binding analysis that brings additional insights into drug kinetics compared to established functional assays.
SPR gives detailed information on affinity, complex half-life, thermodynamic constants and mode-of-action of potential candidates.
In this webinar, you’ll discover how SPR can be multiplexed and automated to enable high-throughput, data-rich drug candidate screening against multiple target proteins.
Watch this webinar to discover:
- The relevance of kinetics and SPR for your drug development project
- The value of multiplexing assays for drug development
- Bruker’s newest Triceratops SPR #64, its flexibility and throughput in drug discovery and development pipelines
Speaker
Cyrill Brunner, Ph.D., Senior Application Scientist, Bruker Switzerland, Fällanden, Switzerland
For Research Use Only. Not for use in clinical diagnostic procedures.